BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
177 results:

  • 1. How to manage waldenström's macroglobulinemia in 2024.
    Grunenberg A; Buske C
    Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A Rare Case of Non-IgM Lymphoplasmacytic lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.
    Yin J; Bains A; Alsammak M; Fu JJ
    Am J Case Rep; 2024 Mar; 25():e940963. PubMed ID: 38437184
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Pathogenesis and Targeted treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
    Chen ZW; Wang SX; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):308-312. PubMed ID: 38387940
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Thymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells.
    Patel SK; Zhdanovskaya N; Sergio I; Cardinale A; Rosichini M; Varricchio C; Pace E; Capalbo C; Locatelli F; Macone A; Velardi E; Palermo R; Felli MP
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338689
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
    Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. cxcr4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
    Werner R; Haug A; Buske C; Heidegger S; Illert AL; Bassermann F; Herhaus P; Buck A; Duell J; Topp MS; Kraus S; Einsele H; Lapa C; Raderer M; Lenz G; Habringer S; von Tresckow B; Keller U
    Nuklearmedizin; 2024 Apr; 63(2):57-61. PubMed ID: 38190998
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. cxcr4-directed PET/CT with [
    Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.
    Dreher N; Dörrler AL; Kraus S; Higuchi T; Serfling SE; Samnick S; Einsele H; Grigoleit GU; Buck AK; Werner RA
    Clin Nucl Med; 2024 Feb; 49(2):146-151. PubMed ID: 38081189
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
    Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
    J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone lymphoma.
    Duell J; Buck AK; Hartrampf PE; Schlötelburg W; Schneid S; Weich A; Dreher N; Lapa C; Kircher M; Higuchi T; Samnick S; Serfling SE; Raderer M; Rasche L; Einsele H; Topp MS; Kosmala A; Werner RA
    J Nucl Med; 2023 Dec; 64(12):1889-1894. PubMed ID: 37797975
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
    Au TY; Arudkumar J; Assavarittirong C; Benjamin S
    Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Theranostics in Hematooncology.
    Buck AK; Serfling SE; Kraus S; Samnick S; Dreher N; Higuchi T; Rasche L; Einsele H; Werner RA
    J Nucl Med; 2023 Jul; 64(7):1009-1016. PubMed ID: 37290799
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting cxcr4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
    Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
    Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. 68Ga-Pentixafor PET/MRI for treatment Response Assessment in Mantle Cell lymphoma: Comparison Between Changes in Lesion cxcr4 Expression on PET and Lesion Size and Diffusivity on MRI.
    Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
    Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
    Moreno DF; Fernández de Larrea C
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):659-670. PubMed ID: 37211494
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Differential Response of Mycosis Fungoides Cells to Vorinostat.
    Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
    Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.
    Tam CS; Kapoor P; Castillo JJ; Buske C; Ansell SM; Branagan AR; Kimby E; Li Y; Palomba ML; Qiu L; Shadman M; Abeykoon JP; Sarosiek S; Vos J; Yi S; Stephens D; Roos-Weil D; Roccaro AM; Morel P; Munshi NC; Anderson KC; San-Miguel J; Garcia-Sanz R; Dimopoulos MA; Treon SP; Kersten MJ
    Semin Hematol; 2023 Mar; 60(2):118-124. PubMed ID: 37099031
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Highly Sensitive Detection Method of cxcr4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies.
    Markou AN; Bagratuni T; Tsakiri C; Tserpeli V; Skourti S; Mavrianou Koutsoukou N; Papadimou A; Terpos E; Kastritis E; Lianidou E; Dimopoulos MA
    J Mol Diagn; 2023 Jul; 25(7):502-512. PubMed ID: 37088135
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 9.